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Abstract
Introduction: BLyS and APRIL are cytokines from the tumor necrosis factor family which play an important role in
systemic lupus erythematosus (SLE). Previous works suggested an association between both molecules and SLE
disease activity although their correlation with lupus nephritis is not known. We therefore assessed serum BLyS and
APRIL in active lupus nephritis patients.
Methods: Serum samples from active lupus nephritis and at 6 months post-treatment were obtained. Serum levels
of BLyS and APRIL (n = 47) as well as renal mRNA expression were measured. Serum levels of both molecules and
clinical data (n = 27) were available at 6 months follow-up. All biopsy-proven lupus nephritis patients were treated
with similar immunosuppressive drugs.
Results: Serum levels of APRIL were associated with proteinuria (Rs = 0.44, P value < 0.01) and degree of
histological activity (Rs = 0.34; P value < 0.05) whereas BLyS levels were associated with complement levels (Rs =
0.46; P value < 0.01) and dosage of immunosuppressant. Interestingly, serum APRIL as well as its intrarenal mRNA
levels were associated with resistance to treatment. From the receiver operating characteristic (ROC) analysis, high
levels (> 4 ng/mL) of serum APRIL predicted treatment failure with a positive predictive value of 93 percent.
Conclusion: APRIL could be a potential biomarker for predicting difficult-to-treat cases of lupus nephritis.
Introduction
B cell regulation plays an important role in the pathogen-
esis of systemic lupus erythematosus (SLE) and lupus
nephritis (LN) [1,2]. Many approaches have targeted
blocking specific pathways of B cell activation for the
treatment of the disease. It has also been shown that when
B cells were depleted, this could ameliorate the progres-
sion of the disease [3-7]. Anti-CD20 monoclonal antibody
was able to normalize autoantibodies and serum comple-
ment levels even though its clinical efficacy for lupus
nephritis was a failure in clinical trials [8]. However, selec-
tion criteria for participants in the trials are vital, and this
may partly be the explanation for the failure. A prognostic
biomarker would therefore greatly help future clinical
trials in selecting more appropriated participants.
B lymphocyte stimulator (BLyS) and a proliferation-
inducing ligand (APRIL) are associated with mechanisms
of disease. These proteins are found in plasma and mem-
branes of monocytes, macrophages and dendritic cells.
Both can activate B cells and plasma cells to proliferate,
differentiate and engage in immunoglobulin G (IgG) class
switching [9-11]. Overexpression of BLyS has been shown
to cause arthritis and nephritis in mice [12] and by block-
ing its receptor, one could prevent the development of LN
[13]. High serum levels of both proteins are found in SLE
patients [14,15]. Furthermore, aberrant expression of both
cytokines in memory and plasma cells were tightly corre-
lated with the disease activity score and autoantibody
production [16].
Both APRIL and BLyS are found in local tissue like
lymph node, bone marrow, synovium and kidney [17-20].
APRIL was also abundant in the cerebrospinal fluid of
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neuropsychiatric lupus [21]. Since APRIL protein was
predominantly found in active lupus nephritis and was
locally produced by the glomerular mesangium [22],
therefore it may be able to determine the prognosis for
lupus nephritis patients. In this study, we assessed the
levels of serum and intrarenal APRIL levels in a prospec-
tive cohort of active lupus nephritis and its correlation
with response to treatment.
Materials and methods
Research design
This is a longitudinal study that was conducted from
March 2005 through June 2010 at the Lupus Research
Unit, Department of Medicine, King Chulalongkorn Mem-
orial Hospital (KCMH). All samples were stored at -80°C
until analysis.
The study was approved by the Ethics Committee for
Human Research of the Faculty of Medicine, Chulalong-
korn University (IRB No. 201/52), and written informed
consent was obtained from all patients.
Study population
All patients who had an SLE classification according to the
1997 criteria established by the American College of Rheu-
matology (ACR) were recruited from KCMH. Fifty-two
patients with active LN were enrolled into the study. The
criteria for active LN were urine proteinuria > 0.5 g/day
and urine red blood cells (RBC)/white blood cells (WBC) >
5/high power field (HPF) or increased serum creatinine >
0.3 mg/dL [23]. Active LN patients were also required to
have a kidney biopsy with an adequate number of glomer-
uli (more than 10) so the severity of LN could be evaluated.
Twenty-seven patients with biopsy-proven ISN/RPS
class III/IV LN were treated with mycophenolate mofetil
(MMF) or intravenous cyclophosphamide plus prednisone.
Blood samples from these patients were drawn at baseline
and six months later. All patients were classified as com-
plete response (CR) or non-CR (partial and non-response)
according the ACR criteria [24]. CR means urine protein
less than 200 mg per day, urine red blood cells less than 5
per high power field and improved kidney function.
Data collection
Various data were collected: clinical assessment of SLE
Disease Activity Index (SLEDAI), laboratory tests, histolo-
gical parameters, blood levels of APRIL and BLyS, and
measurements of APRIL and BLyS levels from the kidney
biopsies. Blood levels of APRIL and BLyS were obtained
on the day of the biopsy and on the next six month fol-
low-up visit.
ELISA measurements for APRIL and BLyS
Enzyme-linked immunosorbent assay (ELISA) was used
to quantify levels of APRIL. ELISA plates (R&D Systems,
Inc., Minneapolis, MN, USA) were coated with mouse
anti-human APRIL polyclonal antibody. Standards and
samples were pipetted into the wells. Any APRIL present
in the patients’ samples were bound by the antibody
coated on the plate. After washing the plate for any
unbound substances, polyclonal antibodies against
APRIL conjugated to horseradish peroxidase were added
to the wells. After that, the plate was washed again to
remove any unbound antibody-enzyme reagent. Next, a
substrate (tetramethylbenzidine) was added to the wells.
The plate was incubated at room temperature in the dark
for a couple of minutes. When the color changed from
blue to yellow, sulfuric acid was added to stop the color
development. The amount of APRIL correlated with the
intensity of the color. The plate was read at a wavelength
of 540 nm or 570 nm.
BlyS was quantitated by the BlyS Platinum ELISA kit
(eBioscience, San Diego, CA, USA). The procedure of
the ELISA is the same as that used to quantitate the
levels of APRIL except for the antibodies used, which
would be more specific in detecting BlyS.
For serum APRIL or BLyS levels, measurement was per-
formed in duplication for each samples. The coefficient
variation (CV) was calculated and any measurement with
CV above 20% was excluded from the analysis. Then, five
out of fifty-two samples were excluded due to CV > 20%.
RNA extraction and cDNA synthesis
RNA was extracted from the renal biopsy specimens of the
LN patients. Total RNA was purified by RNeasy purifica-
tion kit (Qiagen, Valencia, CA, USA). The first strand
cDNA was synthesized from 250 ng of total RNA by using
MultiScribe™ Reverse Transcriptase enzyme (Applied
Biosystems, Carlsbad, CA, USA). The reaction was per-
formed at 45°C for 45 min.
Quantification of intrarenal mRNA levels of APRIL and
BLyS
Intrarenal mRNA levels of APRIL and BLyS were mea-
sured by real-time quantitative polymerase chain reaction
(RT-PCR). The sequences of the primers are as follows:
APRIL sense 5’-AGAGTCTCCCGGAGCAGAGTT-3’,
APRIL antisense 5’-CTGGTTGCCACATCACCTCTGT-
3’, BLyS sense 5’-TCACCGCGGGACTGAAAATCTT-3’
and BLyS antisense 5’-AGCTGAGAAGCCATGGAA-
CAAATG-3’. Each PCR was carried out in a 20 μL reac-
tion volume composed of 2 μL cDNA template, 10 μL of
SYBR Green PCR Master Mix (Applied Biosystems, Carls-
bad, CA, USA), 0.5 mM forward primer, and 0.5 mM
reverse primer. The amplification reaction was performed
by using an Applied Biosystems 7500 Real-Time PCR Sys-
tem (Applied Biosystems, Carlsbad, CA, USA). The com-
parative Delta Ct method was used to determine the
mRNAs levels of APRIL and BLyS. 18s ribosomal RNA
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was used as the endogenous reference. Dissociation curve
analysis confirmed amplification of one specific product
per primer pair.
Renal histology
Paraffin sections were stained with hematoxylin and eosin,
periodic acid-Schiff, trichrome, and silver for light micro-
scopy. Activity and severity of the specimens were scored
by using the Austin criteria [25]. The maximum scores of
the activity and chronicity indices were 24 and 12, respec-
tively. The activity index was calculated by summing the
semi-quantitative scores of the following parameters:
endocapillary proliferation, fibrinoid necrosis, cellular cres-
cents, leukocyte infiltration, hyaline thrombi and intersti-
tial infiltration. The chronicity index was calculated by
adding the semi-quantitative scores of the following para-
meters: glomerular sclerosis, fibrous crescents, interstitial
fibrosis and tubular atrophy. The percentage of each para-
meter was calculated by the following equation:
Percentage of each pathology =
Number of glomeruli involved × 100%
Total number of glomeruli obtained
All biopsies were examined by one pathologist (WK)
who was not aware of the molecular results. The histo-
logical samples of LN were classified according to the
ISN/RPS classification [26].
Renal SLEDAI
Renal SLE disease activity index of the SLE patients at the
time of visit was measured by using MEX-SLEDAI scoring
system [27]. From the MEX-SLEDAI scoring system, the
renal disease activity was scored on a 0 to 16 point scale
according to the MEX-SLEDAI index. A higher score indi-
cated a greater disease activity. Renal SLEDAI was calcu-
lated by summing the scores of the following parameters:
urinary casts (heme-granular or red blood cell casts),
hematuria (> 5 RBC/HPF by excluding stones, infections,
or other causes), proteinuria (> 0.5 gram/24 hours) and
pyuria (> 5 WBC/HPF by excluding infections). The maxi-
mum score of renal SLEDAI was 16.
Data analysis
Statistical analysis was performed by using SPSS software
(version 16, SPSS Inc, Chicago, IL, USA). Continuous vari-
ables were summarized as mean ± SE or median (inter-
quartile range: IQR) where appropriate and categorical
variables were used as frequencies and percentages. Signif-
icant differences were calculated by using Mann-Whitney
tests for continuous variables. Correlation coefficients
were calculated by Spearman’s test. Significant factors
obtained from univariate analysis were entered into a mul-
tiple logistic regression model for control of potential con-
founding effects. Box plot graphs were done by using
GraphPad Prism version 4.03 for Windows (GraphPad
Software, San Diego, CA, USA). The receiver operating
characteristic curve (ROC) curve of APRIL levels was
plotted by using SPSS software. Differences with a P value
of < 0.05 were considered statistically significant.
For serum APRIL or BLyS levels, measurement was
performed in duplication for each sample. The coeffi-
cient variation (CV) was calculated and any measure-
ment with CV > 20% was excluded from the analysis.
Results
Patient characteristics
All studied patients were biopsy-proven class III or IV by
the ISN/RPS classification, which represented common
types of renal pathology of the disease. Other histological
classes were excluded from this study. The mean age of
the patients was 32.9 years. Most of the patients were
female (96%). The mean duration of the disease before
kidney biopsy was 5.9 years. Median renal SLEDAI score
in the active group was 12. Median daily dose of predniso-
lone was 16 mg. Immunosuppressive drugs mostly used in
the study were either oral mycophenolate or pulse intrave-
nous cyclophosphamide. Most of the patients had nephro-
tic range proteinuria with normal serum creatinine. Levels
of serum complements (C3,) were low whereas the anti-
nuclear antibodies (ANA) and anti-dsDNA titers were
high. Mean activity and chronicity scores were 7.83 and
3.01, respectively (Table 1). Here, the studied participants
clearly represented active lupus nephritis in clinical
practice.
The correlation of serum BLyS and APRIL levels with SLE
We studied the stored blood samples drawn at the time
of clinically and histologically confirmed active nephritis.
The immunosuppressant mostly used were moderate
dose of prednisone plus either mycophenolate mofetil or
intravenous cyclophosphamide. BLyS levels were signifi-
cantly correlated with the serum complement level
(Rs = 0.46 for C3; P value < 0.01), total white blood cell
count (Rs = -0.48; P value < 0.01), but not anti-dsDNA
titer. Moreover, BLyS levels were also associated with
dosage of immunosuppressant including steroids and
MMF (Rs = 0. 46 and 0.37; respectively; P value < 0.01)
(Table 2). In a multivariate analysis, MMF was the only
factor associated with BLyS levels (P < 0.01).
APRIL levels were significantly correlated with protei-
nuria (Rs = 0.44; P value < 0.01), and renal histology
activity index (Rs = 0.34; P value < 0.05) (Table 2,
Figure 1). These findings emphasize the differential
functions of both proteins. While BLyS was influenced
by immunosuppressants, APRIL narrowly determined
renal-specific disease activity. Since the correlation study
was based on a single blood sampling test, the better
conclusion would require serial measurement of the
cytokines.
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Serum levels of APRIL were positively correlated with the
severity of renal histology
Serum levels of APRIL in the active (class III/IV) LN ran-
ged from 0.7 to 11 ng/ml with a mean ± SE of 4.1 ± 0.28
ng/ml. In this active LN study, we found that the serum
levels of APRIL were positively correlated to the renal
histology results. Serum levels of APRIL were also posi-
tively correlated with urine protein (Rs = 0.44; P value <
0.01) and renal pathology (Rs = 0.34; P value < 0.05) as
shown in Figure 1. Cutoff for serum level of APRIL was
established by using the mean serum levels of APRIL
from the active LN group; patients with high serum levels
of APRIL (> 4 ng/ml) had more severe renal histology
results as shown in Table 3.
Serum levels of APRIL may predict the patients’
responses to immunosuppressive treatment
To determine the prognostic value of serum APRIL and
BLyS, a prospective cohort with standard immunosuppres-
sive drugs were studied. Twenty-seven patients with
biopsy-proven ISN/RPS class III/IV LN were longitudin-
ally followed and studied after receiving six months of
treatment with immunosuppressive drugs. Serum levels of
BLyS and APRIL were obtained from baseline and at six
months later. In this analysis, we determined the criteria
of complete response to treatment by the ACR criteria
[24].
After six months of immunosuppressive therapy, 30%
(7 of 27) of the patients achieved complete response
(CR). There were no differences in the serum levels of
BLyS among the CR and non-CR prior to treatment
(Figure 2A). However, the serum levels of APRIL from
the CR group were lower when compared to the non-
CR group, but had not reached statistical significance
(Figure 2B). Six patients from the CR group (86%) had
serum levels of APRIL less than 4 ng/ml prior to treat-
ment (Figure 2B). Unlike the CR group, 14/20 (70%)
patients from the non-CR group had serum levels of
APRIL more than 4 ng/ml prior to treatment. We there-
fore performed the ROC; we found that the serum levels
Table 1 Patient characteristic at baseline.
Active LN* (n =
47)
Age, years




Duration of SLE, years




Prednisone use, number (%) 47 (90)
Median dosage, mg/day 16.00







Extrarenal manifestation, number (%) 12 (23)
BLyS, ng/mla 1.32 ± 0.15
APRIL, ng/mla 4.10 ± 0.30
Serum creatinine, mg/dl 1.06 ± 0.08
Proteinuria, g/day





C3 (normal range: 70-140 mg/dL) 60.86 ± 6.05,
ANA, titer 731.20 ± 606.29
Anti-dsDNA, titer 351.74 ± 73.76
Histological parameters
Activity score 7.83 ± 0.70
Chronicity score 3.01 ± 0.37
*Includes only lupus nephritis class III or IV by ISN/RPS 2003 criteria, ‡ renal-
SLEDAI (Systemic Lupus Erythematosus Disease Activity Score) uses four
endpoints as follows: UPCI or 24-hour urine protein ≥0.5 g/day, urinary RBCs
≥5/HPF, urinary WBCs ≥5/HPF and urinary cellular casts ≥1/HPF; and the
maximal point was set at 16. aData are expressed as mean ± SE. ANA,
antinuclear antibody; APRIL, a proliferation-inducing ligand; BlyS, B
lymphocyte activation protein; HPF, high power field; LN, lupus nephritis; RBC,
red blood cells; SLE, systemic lupus erythematous; WBC, white blood cells.
Table 2 Correlations of serum levels for BLyS and APRIL
to lupus activity parameters, pathological scores, and




Serum creatinine mg/dl 0.06 0.06
Erythrocyturia cells/high power field -0.13 0.06
Urine protein g/day -0.05 0.44**
Activity score -0.11 0.34*
Chronicity score 0.25 0.20
Lupus parameters
ANA titer -0.20 0.02
Anti-dsDNA titer -0.28 0.23
Complement factor 3 mg/dl 0.46** -0.44**
Total leukocyte count cells/mm3 -0.49*** 0.26
Polymorph cells/mm3 -0.40** 0.18
Lymphocyte cells/mm3 -0.42*** -0.14
Treatment
Prednisolone mg/day 0.46*** 0.25
Mycophenolate mg/day 0.37** -0.09
ANA, antinuclear antibody; APRIL, a proliferation-inducing ligand; BlyS, B
lymphocyte activation protein; R_SLEDAI, renal Systemic Lupus Erythematous
Disease Activity Index. *P < 0.05, **P < 0.01, ***P < 0.001.
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of APRIL at 4 ng/ml could accurately predict response
to treatment with a sensitivity of 65% and a specificity
of 87.5%. The calculated area under the ROC curve was
0.713 (95% confidence interval = 0.49 to 0.93). The posi-
tive predictive value (PPV) and negative predictive value
(NPV) were 93% and 54%, respectively. This cutoff level
is the same value as the one obtained earlier from the
mean serum levels of APRIL. This indicated that the
value selected for the cutoff was appropriate in distin-
guishing response to treatment.
After six months of immunosuppressive treatment,
there was a significant reduction in serum levels of
APRIL (4.30 +/- 0.39 ng/mL at baseline, and 2.00 +/-
0.26 ng/mL at sixth month; P < 0.001 paired t test)
while serum BLyS levels slightly increased (1.51 +/- 0.24
ng/mL at baseline, and 2.04 +/- 0.28 ng/mL at sixth
month; P = 0.04) (Figures 3A and 3B). This finding may
represent a balance between the two cytokines.
Intrarenal levels of APRIL and BLyS could determine the
response to treatment
It was interesting to further study intrarenal BLyS and
APRIL levels of lupus patients. Renal tissue samples from
36 patients with biopsy-proven class III/IV LN were used
to assess the intrarenal levels of APRIL and BLyS. This
was done by measuring the levels of mRNA from the renal
biopsy samples. The studied samples were divided into
two groups according to the patients’ response to
treatment: responder (n = 18) and non-responder (n =
18). In this analysis, responder were defined by the follow-
ing clinical criteria: (1) stable or improved renal function,
(2) X50% reduction in hematuria to less than 10 RBC per
HPF and (3) significant reduction in proteinuria (X50%
reduction to less than 3 g/day if baseline is within the
nephrotic range or less than 1 g/day if baseline is not
nephrotic) for at least three months.
The non-responder group had significantly higher
mRNA levels of APRIL and BLyS compared to the respon-
der group (Figures 4A and 4B). Intrarenal mRNA levels of
BLyS were significantly and positively correlated with
intrarenal mRNA levels of APRIL as shown in Figure 4C,
(r = 0.692; P < 0.01). This result suggests that both APRIL
and BLyS may play a role in the severity of renal inflamma-
tion. Therefore, the intrarenal mRNA levels of APRIL and
BLyS may be used to predict the outcome of treatment.
We also studied paired serum and kidney tissues
obtained on the same day (n = 20). The serum APRIL
or BLyS was not associated with its intrarenal levels
(data not shown). However, the relationship between
circulating and intrarenal APRIL/BLyS warrants further
study. Here, we speculate that local factors could also
influence intrarenal gene expression.
Discussion
This study demonstrated that B cell activation markers
such as APRIL and BLyS are tightly correlated with SLE
Figure 1 The correlation between blood levels for APRIL, activity index and 24-hour urine protein. The relationship between the blood
levels for APRIL and renal histology in active LN (A) was significantly correlated with a P value of < 0.05 (r = 0.34). The blood levels for APRIL
and 24-hour urine protein (B) were also significantly correlated with P value of < 0.01 (r = 0.44).
Table 3 Serum levels of APRIL and activity score from the renal histological outcomes.
Percentage of glomeruli with the lesions Blood APRIL≤4 ng/ml Blood APRIL > 4 ng/ml P value
Endocapillary proliferation 40.99 ± 6.76 64.87 ± 8.6 0.033*
Fibrinoid necrosis 4.69 ± 2.15 12.66 ± 4.1 0.012*
Neutrophil infiltration 16.47 ± 4.85 49.59 ± 8.95 0.004*
Hyaline deposit 22.74 ± 7.37 27.65 ± 7.36 0.609
Cellular crescent 12.38 ± 3.49 15.12 ± 4.27 0.620
*The cutoff level for blood APRIL was 4 ng/ml. This cutoff value was obtained from the average blood levels of APRIL from all patients studied. APRIL, a
proliferation-inducing ligand.
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and LN disease activity. Serum levels of BLyS were
influenced by immunosuppressant whereas serum levels
of APRIL could accurately predict the status of the kid-
ney and severity of the disease (Table 2). Patients with
high serum levels of APRIL have severe proliferative
nephritis such as endocapillary proliferation, fibrinoid
necrosis and polymorph infiltration. In addition, serum
levels of APRIL more than 4 ng/mL may predict that
the patients will experience treatment failure (Table 3
and Figure 2). Moreover, in non-responder patients,
intrarenal mRNA levels of APRIL and BLyS were higher
compared to the responders (Figure 4). This supported
the notion that blocking BLyS and APRIL may be useful
in treating lupus nephritis.
BLyS and APRIL have been shown to be involved in B
cell-mediated pathology of SLE. In an animal model, it has
been shown that BLyS transgenic mice had an elevated
number of B cells with prolonged survival times [28]. These
transgenic mice exhibited lupus-like phenotypes such as
having high titer levels of anti-dsDNA antibody, protei-
nuria, and glomerulonephritis [28,29]. It has been shown
that by blocking the receptors of BLyS and APRIL, TACI-
Ig can decrease levels of proteinuria in NZB/W F1 lupus-
prone mice [29]. On the other hand, by blocking only BLyS,
BAFF-R-Ig has been shown to be able to prolong the lives
of NZB/W F1 mice and prevent renal inflammation [30].
These data obtained from the animal studies were con-
sistent with findings in lupus patients. Chu et al. [16]
found expressions of BLyS and APRIL on CD19+ B cells
that were closely correlated with the activities of the dis-
ease and autoantibody levels in SLE patients. We also
observed an elevated level of circulating BLyS [29], which
corresponded to the serologic indices of SLE patients
(Table 2). Interestingly, dosages of immunosuppressive
drugs affected serum levels of BLyS and APRIL differently
(Figure 3A and 3B). Serum levels of both cytokines in this
study may release from different B-cell populations [31].
BLyS represents early preimmune B-cell stages and could
be easily inhibited by steroids or MMF [32]. In contrast,
APRIL may lately respond to the immunosuppressants.
We observed high APRIL levels associated with lupus
patients without renal involvement and only used low-
dose prednisone (data not shown). This was previously
demonstrated by Morel et al. [33].
Figure 2 Comparisons of blood levels for BLyS (A) and APRIL (B) and treatment response. Each dot represents a baseline serum level of
individual patient. CR means complete response to treatment by ACR criteria. Non-CR means partial or non-responses. ACR, American College of
Rheumatology; APRIL, a proliferation-inducing ligand; BlyS, B lymphocyte activation protein.
Figure 3 Changes in blood levels for BLyS and APRIL after six months of treatment in active LN patients. Dots and bars show blood
levels for BLyS (A) and APRIL (B) in patients with active LN class III or IV at baseline and 180 days posttreatment. APRIL, a proliferation-inducing
ligand; BlyS, B lymphocyte activation protein; LN, lupus nephritis.
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Regarding circulating BLyS levels, we observed less
serum BlyS levels (1.32 ± 0.15 ng/mL) as compared to
other studies (range 1.5 to 19.1 ng/mL) [34]. In contrast
to previous published works [34,35], all participants, in
this study, were diagnosed lupus glomerulonephritis and
had marked proteinuria. As Petri M and Stohl W et al.
pointed out that lupus nephritis may have a urinary loss
of BLyS protein. Therefore, a loss of correlation between
circulating BLyS and disease activity may occur in lupus
nephritis [34,35]. Unlike other published works, we did
not find a correlation between BLyS and anti-dsDNA.
This could be explained by the urine loss of BLyS pro-
tein. Moreover, potent immunosuppressants (steroids
and MMF) may decrease BlyS production while such
treatment had less influence on the anti-dsDNA titer
[32]. Therefore, different results among published works
could be explained by different stages of disease and stu-
died populations.
The utility of biomarkers in clinical nephrology has been
successfully demonstrated by leaders in the field [36,37].
Since serum APRIL levels were associated with the histol-
ogy of nephritis, and high serum levels (> 4 ng/mL) of
APRIL may predict treatment failure in patients with class
III/IV LN on standard course of therapy. Thus, levels of
APRIL may be used as a biomarker to prognose or guide
the treatment for LN. This would indicate that patients
with class III/IV LN and high serum levels of APRIL will
need additional therapy in conjunction with the standard
Figure 4 Correlations of intrarenal mRNA levels for APRIL and BLyS and response to treatment. Box plots and bars show mRNA levels for
APRIL (A) and BLyS (B) from the renal tissues of the non-responder (n = 18) and responder groups (n = 18). The mean mRNA levels for APRIL
and BLyS from the non-responder group were significantly higher when compared to the patients from the responder group (*P = 0.02, #P =
0.007). Dots and bars in (C) represent the correlated expression of mRNA levels for BLyS and APRIL in the renal tissue of patients with LN (r =
0.692; P < 0.01). APRIL, a proliferation-inducing ligand; BlyS, B lymphocyte activation protein; LN, lupus nephritis.
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immunosuppressive treatment in order to successfully
treat the disease.
The use of monoclonal antibodies such as belimumab
together with standard therapy has been shown to work
in treating patients with mild forms of SLE without renal
or neurological organ involvement [38-40]. Although
belimumab is the only monoclonal antibody that has
already been approved to treat SLE, monoclonal antibo-
dies to APRIL/BLyS are ongoing in clinical trials. Current
treatment for severely active LN are only limited to
immunosuppressants such as steroids, cyclophosphamide
or mycophenolate. For non-responsive LN patients, they
will inevitably progress to end-stage kidney disease.
Currently, there are clinical trials assessing the safety
and efficacy of monoclonal antibodies to BLyS/APRIL
such as atacicept. The recombinant protein, atacicept, was
studied in phase II/III trial together with MMF and steroid
in newly active LN. Unfortunately, patients who received
atacicept had profound hypogammaglobulinemia and
infection [41]. Combination use of atacicept with MMF is
therefore prohibited. In order to sufficiently evaluate the
safety and efficacy of these antibodies, selection of partici-
pants with active LN is extremely crucial. Based on the
results obtained from our study, we postulate that LN
patients with high serum levels of APRIL may benefit
from using atacicept or other targeted APRIL therapy.
Equally important, our study has shed some light on the
pathogenesis of LN. We postulate that local factors may
control these gene expressions. BLyS/APRIL mRNAs and
proteins were previously observed in the glomerulus and
inflammatory infiltrating cells [22]. This would indeed
explain why our patients with high intrarenal mRNAs
were resistant to treatment. Excess levels of APRIL and
BLyS may promote survival of autoreactive B cells in the
kidney, causing an increased production of pathogenic
autoantibodies, and finally resulting in immune-complex-
induced glomerulonephritis.
There were some limitations encountered in this study.
Aside from the rather small sample size in this study, the
studied samples were collected from patients who received
different immunosuppressive therapies. Therefore, a further
validation study on samples collected before initiation of
immunosuppressant should be done in a prospective clini-
cal trial. Nonetheless, this study clearly showed that the B
cell activation biomarkers were present in the circulation
and kidney tissues of active lupus nephritis patients.
Conclusions
This study supported the pivotal role for both soluble and
tissue levels of APRIL and BLyS in lupus nephritis
patients. Since serum levels of APRIL were specific to
renal involvement, it may be used as a non-invasive prog-
nostic biomarker for severe LN. Blocking APRIL may be a
new way to treat patients with difficult-to-treat LN.
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